The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
20 billion
PE Ratio
76.21 x
Beta (volatility)
0.93
Earnings Per Share
2.69
About
produces and sells instruments and consumables for the biopharmaceutical industry worldwide.
The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for...
Price
Performance Comparison
| Sartorius Stedim Biotech S.A | |
|---|---|
| 1 year return |
+8 %
|
| 5 years return |
-41 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 4.28 | 30 % | 1.11 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 7.17 | 42.15 | 6.45 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
15 years
Frequency
1x / year
Dividends in 2024
April
Dividends in 2023
April
April
Dividends in 2023
April
Forward Annual Amount
$0.76
Ex-dividend
4/3/2025
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
News
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
8/11/2025
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
7/29/2025
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform
7/9/2025
Sartorius Stedim Biotech SA (SDMHF) Q1 2025 Earnings Call Highlights: Strong Bioprocess Growth ...
4/17/2025
Sartorius Stedim Biotech SA (SDMHF) Q4 2024 Earnings Call Highlights: Navigating Growth Amid ...
1/31/2025
Sartorius Stedim Biotech SA (SDMHF) Q3 2024 Earnings Call Highlights: Navigating Market ...
10/18/2024
SARTORIUS (SARTF) Q3 Earnings Lag Estimates
10/19/2023
Sartorius’s Shares Drop on Outlook Cut, Preliminary 3Q Declines
10/13/2023
UPDATE 2-Sartorius to buy Polyplus for 2.4 bln euros
3/31/2023
Nine-month results 2022 of Sartorius Stedim Biotech
10/19/2022
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions
8/8/2022
Half-year results 2022 of Sartorius Stedim Biotech
7/21/2022
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2025 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.